Self-assessment Q&A in Clinical Laboratory Science, III

Alan H.B. Wu

• Publisher: Elsevier
• Year: 2020
• ISBN:
  9780128220948
• Topic: Medicina
• Subtopic: Tecnologia e forniture mediche

Self-assessment Q&A in Clinical Laboratory Science, III, adds a variety of subject matter that addresses new concepts and emerging technology, particularly in the areas of kidney biomarkers, cancer biomarkers, molecular diagnostics, multiple myeloma, pharmacogenomics, novel cardiovascular biomarkers and biomarkers of neurologic diseases. The field of Clinical Laboratory Science continues to evolve and editor Alan Wu has once again brought together experts in the field to cover the contemporary topics that are being tested today. This updated bank of questions and answers is a must-have to sharpen knowledge and skills.

• Contains nearly 800 multiple choice questions with correct answer explanations
• Assists readers in determining knowledge gaps so they can better study for certification examinations and remain current in this rapidly changing field
• Provides a format that is conducive to quick learning in digestible segments
• Includes beneficial citations for additional study

Section A

General clinical chemistry

Chapter 1: Antiquated and novel clinical laboratory tests

Alan H.B. Wu University of California, San Francisco, CA, United States

1. 1. Which of the following tests may be unnecessary in light of grain supplementation that occurs in North America?
   1. a. mean corpuscular volume
   2. b. vitamin B12
   3. c. serum folate
   4. d. homocysteine
   5. e. methylmalonic acid
2. 2. Which of the following test is largely obsolete with regards to pancreatic disease?
   1. a. amylase
   2. b. lipase
   3. c. serum trypsin
   4. d. CA19-9
   5. e. secretin
3. 3. Which test is most appropriate for testing fetal lung maturity, replacing all of the others listed?
   1. a. lecithin:sphingomyelin ratio
   2. b. foam stability index
   3. c. phosphatidyl glycerol
   4. d. lamellar body count
   5. e. FLM test (surfactant-to-albumin ratio)
4. 4. Which cardiac marker is largely antiquated?
   1. 1. myoglobin
   2. 2. creatine kinase-MB
   3. 3. lactate dehydrogenase isoenzymes
   4. 4. total creatine kinase
      1. a. 1,2,3
      2. b. 1,3
      3. c. 2,4
      4. d. 4 only
      5. e. all of the above
5. 5. Which of the following is recommended for vitamin D testing?
   1. a. general population screening
   2. b. routine measurement of both hydroxy and dihydroxyvitamin D
   3. c. use of mass spectrometry for D2 and D3 speciation to monitor the effect of supplementation
   4. d. analysis of the C-3 25(OH)D3 epimer in neonates
   5. e. analysis of the C-3 25(OH)D3 epimer in adults
6. 6. Which of the following analytes is not yet standardized by a recognized body?
   1. a. creatinine
   2. b. hemoglobin A1c
   3. c. cholesterol
   4. d. glucose
   5. e. parathyroid hormone
7. 7. Which of the following is correct regarding the differences between the MDRD and CKD-EPI equations for estimated glomerular filtration rate?
   1. a. The CKD-EPI equation is more accurate at 60 mL/min.
   2. b. The CKD-EPI equation accounts for Asians and Hispanics.
   3. c. The CKD-EPI equation uses cystatin C.
   4. d. The MDRD equation significantly overestimates GFR among individuals with normal kidney function.
   5. e. Neither equation has biases for patients with renal transplant.
8. 8. The MDRD and CKD-EPI use a correction factor for subjects who are African American. On average, this is because African Americans
   1. a. have larger kidneys
   2. b. have larger muscle mass
   3. c. have large fat volume
   4. d. eat more red meat
   5. e. have higher likelihood of reduced kidney function
9. 9. What of the following is true regarding prostatic acid phosphatase today (PAP)?
   1. a. It is synonymous with prostate-specific antigen (PSA).
   2. b. Ratio of PAP/PSA better separates benign prostatic hypertrophy from prostate cancer.
   3. c. Recent data suggests that PAP may be better than PSA for screening.
   4. d. Recent data suggests that PAP may be better than PSA for predicting metastatic disease.
   5. e. No recurring role for PAP.
10. 10. Which of the following is true regarding the use of the erythrocyte sedimentation rate (ESR) vs C-reactive protein (CRP)?
    1. a. Results are concordant 95% of the time, obviating the need for both testing.
    2. b. ESR is more sensitive as an early marker of inflammation.
    3. c. ESR is less sensitive than CRP in patients with bacterial infections.
    4. d. CRP results from an increase in fibrinogen.
    5. e. CRP has a longer half-life.
11. 11. Which of the following tests is rarely used regarding a workup of pernicious anemia?
    1. a. Schilling test
    2. b. methylmalonic acid
    3. c. mean corpuscular volume
    4. d. serum B12 level
    5. e. red cell folate level
12. 12. Which of the following statements do not provide rationale for measuring methylmalonic acid (MMA) and homocysteine for megaloblastic anemia?
    1. a. MMA is an early indicator of B12 deficiency.
    2. b. Serum vitamin B12 levels do not represent functional stores.
    3. c. Homocysteine is elevated in B12 deficiency.
    4. d. MMA concentrations decline with vitamin B12 treatment.
    5. e. MMA is not increased in folate deficiency.
13. 13. Which of the following has not been studied as a marker for traumatic brain injury?
    1. a. S100b
    2. b. myelin basic protein
    3. c. ubiquitin C-terminal hydrolase L1
    4. d. CK-MM Isoenzyme
    5. e. brain-derived neurotrophic factor

1. 14. Which of the following traumatic brain injury markers is released as the result of microvascular injury?
   1. a. glial fibrillary acidic protein
   2. b. neuron specific enolase
   3. c. matrix metalloproteinase
   4. d. tau protein
   5. e. αII-spectrin

1. 15. What may the role of detecting autoantibodies to brain proteins after traumatic brain injury (TBI)?
   1. a. early detection
   2. b. differentiation between health and mild TBI
   3. c. the presence of autoantibodies themselves produce adverse events
   4. d. predicting onset of TBI-induced Parkinson syndrome
   5. e. their absence excludes the need for a head CT scan

1. 16. Which of the following is not a clinical application of measuring anti-Müllerian hormone levels?
   1. a. prediction the age of menopause
   2. b. aid in the diagnosis of polycystic ovary syndrome
   3. c. assessment of ovarian function before and after gynecologic surgeries
   4. d. prediction of ectopic pregnancy
   5. e. predicting the risk for developing ovarian hyperstimulation syndrome

1. 17. Which of t...